The FDA just rejected a liver cancer drug for the third consecutive time, and the reason has nothing to do with whether the drug actually works. Hengrui and Elevar's manufacturing woes are becoming a cautionary tale for every biotech relying on overseas factories.
Imagine acing every exam in medical school but getting expelled because your dorm room is a biohazard. That's essentially what's happening to Hengrui and Elevar Therapeutics right now.
Their liver cancer combo (camrelizumab plus rivoceranib) just got rejected by the FDA for the third consecutive time. Not because the drug doesn't work. Not because it's unsafe. The clinical data has never been questioned. The FDA simply won't approve it because the factories making it can't pass inspection.
Three strikes. All manufacturing. Zero about the medicine itself.
A Hat Trick Nobody Wanted
Let's rewind. The combination targets first-line unresectable hepatocellular carcinoma (advanced liver cancer that can't be surgically removed). Camrelizumab is the PD-1 inhibitor, an immune checkpoint drug that helps your body's T-cells recognize and attack tumors. Rivoceranib is a VEGFR inhibitor that starves tumors by cutting off their blood supply. Together, they showed strong results in a global Phase 3 trial across 95 sites in 13 countries.
The FDA has never disputed those results. Not once across three rejections.
The first Complete Response Letter (CRL, which is FDA-speak for "no, try again") landed in May 2024. Inspectors had visited Hengrui's Suzhou Suncadia facility, the plant making camrelizumab, and came back with a 10-page Form 483 listing ten observations. A Form 483 is basically the FDA's written report card after touring your factory, and ten observations is a terrible grade. The problems included data integrity issues, contamination control failures, and raw material handling concerns.
There were also incomplete clinical site inspections (partly due to travel restrictions for sites in Russia and Ukraine), but the manufacturing issues were the headline.
Fix One Thing, Break Another
Hengrui went back, addressed the problems, and resubmitted in October 2024. The FDA reinspected the camrelizumab plant. And found new deficiencies.
That triggered CRL number two in . Same plant. Different problems. Think of it like fixing the plumbing in your restaurant after a health inspection, only to have the inspector return and find rats in the kitchen.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
March 2025
The clinical data? Still fine. The FDA still had no issues with how the drug performed in patients. But compliance at the Suzhou facility remained below the agency's standards.
Elevar and Hengrui regrouped again. They resubmitted the NDA on January 23, 2026, and the FDA accepted it with a PDUFA target date (the deadline for the agency to make a decision) of July 23, 2026. Both companies signaled that CMC compliance, the shorthand for chemistry, manufacturing, and controls, was "the single most important hurdle" they needed to clear.
They were right about the hurdle. They just didn't clear it.
Plot Twist: Now It's the Other Factory
In April 2026, the FDA inspected a different facility: the one making rivoceranib, the small-molecule half of the combination. This was a separate Hengrui manufacturing site in China, not the Suzhou plant that had caused all the earlier headaches.
New site. New Form 483. New problems.
On July 2, 2026, the FDA issued its third CRL. The agency told Elevar that the application couldn't move forward until the rivoceranib facility demonstrated cGMP (current good manufacturing practice) compliance. The FDA also reserved the right to conduct a pre-approval inspection after remediation before it would even consider saying yes.
The symmetry here is almost poetic in its frustration. The first two rejections were driven by the camrelizumab factory. The third was driven by the rivoceranib factory. The roles reversed, but the outcome was identical: manufacturing problems blocking an otherwise approvable drug.
What the Inspectors Found (And Didn't Find)
The specific observations from the April 2026 rivoceranib inspection haven't been made public. We know a Form 483 was issued, and we know it was serious enough to trigger a CRL. But the individual line items haven't been disclosed.
We do know more about the earlier Suzhou camrelizumab inspections. Trade press described those Form 483s as "scathing," with ten observations covering contamination controls, cleaning procedures, record integrity, and security of injectable waste. Inspectors noted that Hengrui initially failed to provide production records promptly. Discarded batch documentation didn't match official archives, a classic data integrity red flag that makes regulators very nervous.
One particularly alarming finding: potential mix-ups between raw materials intended for Chinese versus US markets. When you're making injectable cancer drugs, mixing up materials for different regulatory markets isn't a paperwork problem. It's a patient safety problem.
Why This Matters Beyond One Drug
About 74% of recent FDA CRLs were driven at least partly by quality and manufacturing issues. That number should make every biotech exec with overseas manufacturing sit up straight. The FDA has been tightening its focus on cGMP compliance for years, and China-based facilities are getting especially close scrutiny.
The Hengrui situation isn't an outlier. It's a case study in a broader trend.
For mid-cap sponsors like Elevar that depend on a single overseas manufacturing partner, the risk calculus is brutal. You can run a flawless clinical program, generate gorgeous survival curves, and still watch your drug sit on the shelf because a factory 7,000 miles away can't keep its records straight.
The $1 Billion Question
The financial stakes are enormous. Elevar's licensing deal with Hengrui includes up to $600 million in sales milestones plus double-digit royalties on camrelizumab. The total payout over 10 years could reach roughly $1 billion. Elevar holds exclusive rights to commercialize the combination everywhere outside Greater China and Korea.
That's a lot of money riding on factory inspections.
When the third CRL hit, HLB Group (Elevar's Korean parent company) reportedly plunged to limit-down levels on the stock exchange. Investors weren't reacting to bad science; they were reacting to a pattern. Three manufacturing rejections in a row creates a narrative that's hard to shake, even when the drug works.
There is a silver lining, though. After the April 2026 inspection, the FDA eventually issued a "close-out letter" classifying the rivoceranib facility as VAI (Voluntary Action Indicated). In FDA language, VAI means: "We found problems, but they're the kind you can fix without us taking formal enforcement action." That's meaningfully better than the alternative classification (OAI, or Official Action Indicated), which would signal the agency believes the facility needs major intervention.
HLB has publicly stated it believes "most of the key issues behind the FDA's delay in approving the drug have now been resolved."
What Comes Next
Elevar and Hengrui say they're preparing corrective actions and plan to resubmit. The playbook is familiar by now: fix the problems, document the fixes, wait for the FDA to reinspect or accept the written responses, then refile.
But analysts expect at least one more full review cycle before any approval decision. The FDA has explicitly said it may require a pre-approval inspection of the remediated rivoceranib site. That takes time.
The broader lesson here extends well beyond one liver cancer drug. Industry experts are increasingly advising sponsors with China-based manufacturing to dual-source or transfer production to US/EU facilities rather than rely on a single overseas site. The era of treating manufacturing compliance as a box to check at the end of drug development is over. The FDA is treating cGMP as co-equal with clinical data when deciding whether to approve a drug.
For Hengrui and Elevar, the path forward is narrow but still visible. The science works. The clinical data is strong. The FDA has said so, repeatedly and explicitly. They just need their factories to pass the test.
After three tries, you'd think they'd have studied for the exam by now.
Clinical & Regulatory4 min read
The Ruling That Just Killed 60,000 Lawsuits
The Supreme Court just ruled that federal law blocks most Roundup cancer lawsuits, potentially wiping out 60,000+ pending claims in a landmark win for Bayer. The decision could reshape how mass tort litigation works for every chemical and drug company in America.
